Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Elemental chlorine or elemental chlorine releasing inorganic...
Reexamination Certificate
2006-09-12
2006-09-12
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Elemental chlorine or elemental chlorine releasing inorganic...
C424S613000, C424S615000, C424S662000, C424S663000, C424S665000, C514S885000
Reexamination Certificate
active
07105183
ABSTRACT:
The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.
REFERENCES:
patent: 4507285 (1985-03-01), Kuhne
patent: 4725437 (1988-02-01), Kuhne
patent: 5877222 (1999-03-01), McGrath
patent: 6086922 (2000-07-01), Kuhne
patent: 2003/0130357 (2003-07-01), Ramesh et al.
patent: 2003/0130360 (2003-07-01), Ramesh et al.
patent: 2003/0158262 (2003-08-01), Ramesh et al.
patent: 2003/0175832 (2003-09-01), Marton et al.
patent: 2005/0129784 (2005-06-01), Kuehne
patent: WO-99-21542 (1999-05-01), None
Jones-London. What's Old is New Again—antibiotic protects nerves by removing excess glutamate. Feb. 7, 2005, Retrieved from the Internet on Nov. 29, 2005. URL: http://www.ninds.nih.gov
ews—and—events
ews—articles
ews—article—ALS—ceftriaxone.htm.
Miller, T. et al., “Treating Neurodegenerative Diseases with Antibiotics,” Science, vol. 307, pp. 361-362 (Jan. 21, 2005).
Rothstein, J.D.et al., “beta-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression,” Nature, vol. 433, pp. 73-77 (Jan. 6, 2005).
Ziegler, T. Doubling up . . . common dietary supplement with an antibiotic to treat Lou Gehrig's Disease. Jan. 31, 2003. Retrieved from the Internet on Nov. 29, 2005. URL: http://www.ninds.nih.gov
ews—and—events
ews—articles
ews—article—als—combination—treat.
Zhu, S. et al., “Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice,” Nature, vol. 417, pp. 74-78 (May 2, 2002).
Habermann, E. et al., “Oxoferin and sodium chlorite—a comparison,” Klin Wochenschr, vol. 67(1), Jan. 1989, pp. 20-25 (English translation).
Biosis Abstract, accession No. 1994:4889101 (1994).
Biosis Abstract, accession No. 1994:163800 (1994).
Medline Abstract, accession No. 2003039765 (2003).
Akiyama et al. Inflammation and Alzheimer's disease, Neurobiol Aging. May-Jun, 2000; 21(3):383-421.
Alexianu et al. Immune reactivity in a mouse model of familial ALS correlates with disease progression, Neurology. Oct. 9, 2001; 57(7):1282-9.
Anderson et al. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol. Jul. 2002: 72(1):101-6.
Appel et al. Evidence for autoimmunity in amyotrophic lateral sclerosis,J. Neurol. Sci, 1993. 118:169-174.
Cremer et al. Antibody titers to coxsackieviruses in amyotrophic lateral sclerosis.N. Engl. J. Med, 1976, 295(2):107-108. (Letter).
Diesing et al. HIV-1-associated dementia: a basic science and clinical perspective,AIDS Read, 2002. 12:358-368.
Engelthardt et al. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis,Arch. Neurol. 1990, 47:1210-1216.
Fiala et al. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier,Eur. J. Clin. Invest. 2002,32:360-371.
Giese et al. Differential effects on innate versus adaptive immune responses by WF10, Cell Immunol. Jun. 2004;229(2):149-58.
Glass et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia.Ann. Neurol, 1995. 38:755-762.
Hansen et al. High-dose stabilized chlorite matrix WF10 prolongs cardiac xenograft survival in the hamster-to-rat model without inducing ultrastructural or biochemical signs of cardiotoxicity. Pharmacol Toxicol. Aug. 2001; 89(2):92-5.
Hayashi et al. Pathological study of the diffuse myelin pallor in the anterolateral columns of the spinal cord in amyotrophic lateral sclerosis,J. Neurol. Sci. 2001,188:3-7.
Hensley et al. Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.J. Neurochem, 2002. 82:365-374.
Hirsch et al. The role of glial reaction and inflammation in Parkinson's disease.Ann N.Y. Acad. Sci, 2003. 991:214-228.
Janssen et al. Nomenclature and research case definitions of neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection.Neurology. 1991,41:778-785.
Kemp et al. Immunosuppression in xenotransplantation with Wf10. Pharmacol. Toxicol. Jun. 2002;90(6):346-8.
Kemp et al. WF10 in xenotransplantation-a potential new approach Transplant Proc. Aug. 2000;32(5):1018-9.
Klaustermeyer et al. Quantitative immunoglobulins and IgG subclasses in patients with corticosteroid-dependent reversible airway obstruction.Ann. Allergy. 1989,63:327-330.
Kott et al. Cell-mediated immunity to polio and HLA antigens in amyotrophic lateral sclerosis.Neurology. 1979,29:1040-1044.
Lehrich et al. Neutralizing antibodies to pollovirus and mumps virus in amyotrophic lateral sclerosis.J. Neurol. Sci, 1974,23:537-540.
MacGowan et al. An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy.Neurology. 2001. 57:1094-10.
Marshall et al. Cytokine dysregulation associated with exam stress in healthy medical students.Brain Behav. Immun. 1998,12:297-307.
McArthur et al. Dementia in AIDS patients: incidence and risk factors.Neurology, 1993, 43:2245-2252.
McGeer et al. The importance of inflammatory mechanisms in Alzheimer disease.Exp. Gerontol. 1998, 33:371-378.
McGeer et al. Inflammatory processes in amyotrophic lateral sclerosis.Muscle Nerve. 2002,26:459-470.
McGrath et al. Effect of WF10 (TCDO) on antigen presentation.Transplant. Proc. 1998,30:4200-4204.
McGrath et al. Balanced macrophage activation hypothesis: a biological model for development of drugs targeted at macrophage functional states.Pathobiology. 1999, 67:277-81.
Minagar et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis.J. Neurol. Sci. 2002,202:13-23.
Mizutani et al. Sensorimotor demyelinating neuropathy with IgM antibody against gangliosides GD1a, GT1b and GM3.J. Neurol. Sci. 2001, (188) 9-11.
Morgan et al. Clinical significance of IgG subclass deficiency.Arch. Dis. Child. 1988,63:771-773.
Moulignier et al. Reversible ALS-like disorder in HIV infection.Neurology. Sep. 2001 57:995-1001.
Nguyen et al. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration.Ann. Neurol. 2001, 50:630-639.
Nottet et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain.J. Immunol. 1996.156:1284-1295.
Obal et al. Recruitment of activated microglia cells in the spinal cord of mice by ALS IgG.Neuroreport. 2001, 12:2449-2452.
Ono et al. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis.J. Neurol. Sci. 2001, 187:27-34.
Ostermeyer-Shoaib et al. IgG subclass deficiency in amyotrophic lateral sclerosis.Acta Neurol Scand. 1993,87:192-194.
Raffanti et al. Randomized, double-blind, placebo-controlled trial of the Immune modulator WF10 in patients with advanced AIDS.Infection. Jul.-Aug.1998;26(4):202-7.
Power et al. Neuroimmune and neurovirological aspects of human immunodeficiency virus infection.Adv. Virus. Res. 2001.56:389-433.
Provinciali et al. Immunity assessment in the early stages of amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets.Acta. Neurol. Scand. 1988,78:449-454.
Pulliam et al. Unique monocyte subset in patients with AIDS dementia.Lancet. 1997, 349:692-695.
Schempp et al. Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite-based drug WF10. ArzneimForschDrugRes. 2001;51(11):554-62.
Schiffer et al. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis.J. Neurol. Sci. 1996,139(suppl):27-33.
Smits et al. Role of macrophage activati
Bozicevic Field & Francis LLP
Francis Carol L.
Pak John
LandOfFree
Chlorite in the treatment of neurodegenerative disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chlorite in the treatment of neurodegenerative disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chlorite in the treatment of neurodegenerative disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525405